Skip to content

Effect of Tripterygium wilfordii polyglycoside tablets on the inhibition of TM on complement pathway and related inflammatory markers in membranous nephropathy

The complement pathway and related inflammatory factor markers in the treatment of idiopathic membranous nephropathy

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000037467
Enrollment
Unknown
Registered
2020-08-28
Start date
2020-12-31
Completion date
Unknown
Last updated
2020-10-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

idiopathic membranous nephropathy

Interventions

Gold Standard:Cell hemolysis test
Index test:Immunochemiluminescence&#32
(ECL)&#32
and&#32
flow&#32
cytometry&#32
(FCM)&#32
were&#32
used&#32
to&#32
the&#32
of&#32
pathway&#32

Sponsors

Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. The clinical and pathological diagnosis was membranous nephropathy; 2. Aged 18-90 years old; 3. the patient was hospitalized within 24 hours after the onset of the disease; 4. there was no history of heart, liver dysfunction, severe anemia, leucopenia and thrombocytopenia.

Exclusion criteria

Exclusion criteria: 1. acute and chronic kidney diseases other than membranous nephropathy; 2. long-term immobilization; 3. recent surgery and blood transfusion; 4. incomplete clinical data; 5. heart and liver dysfunction; 6. severe anemia, leukopenia and thrombocytopenia; 7. patients with active gastric and duodenal ulcer; 8. severe arrhythmia; 9. children, child-bearing age with pregnancy requirements, pregnant women and lactation woman.

Design outcomes

Primary

MeasureTime frame
CH50;Single complement component content;

Countries

China

Contacts

Public ContactLI JI

Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

1037517966@qq.com+86 021-64385700-6314

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026